Antifungal and anti-biofilm effects of shallot (Allium ascalonicum) aqueous extract on Candida albicans by Shan Ng, Tzu et al.
Journal of Herbmed Pharmacology
J Herbmed Pharmacol. 2018; 7(4): 236-242.
Antifungal and anti-biofilm effects of shallot (Allium 
ascalonicum) aqueous extract on Candida albicans
Tzu Shan Ng1,2* ID , Ley Juen Looi3, Ban Shui Ong1, Pei Pei Chong1
1Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia
2Department of Molecular Medicine, Faculty of Medicine, University of Malaya 
3Department of Environmental Science, Faculty of Environmental Studies, Universiti Putra Malaysia
*Corresponding author:  Tzu Shan Ng. Email:tzushang@gmail.com
Implication for health policy/practice/research/medical education:
Candidiasis remains as one of the prominent nosocomial infection disease and Candida biofilm is one of the main culprits 
associated with this deadly disease. The result showed the application of Allium ascalonicum aqueous extract in anti-Candida 
albicans growth and its biofilm activity. This simple and inexpensive method could be useful for the development of surface 
disinfectant in tackling the C. albicans biofilm issue in the clinical setting.
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Introduction: The limited option to combat fungal threat has raised the interest in seeking 
alternative anti-fungal compounds. This study aimed to determine the antifungal property 
of aqueous-extracted shallot (Allium ascalonicum) against Candida albicans, a medically 
important yeast pathogen. The anti-biofilm property of A. ascalonicum aqueous extract was 
also investigated.
Methods: The antifungal effect of A. ascalonicum aqueous extract on C. albicans was screened 
using disc diffusion assay and the minimum inhibitory concentration (MIC) was determined 
using broth macrodilution. Subsequently, the anti-biofilm property of A. ascalonicum aqueous 
extract was investigated using 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino) 
carbonyl]-2 H-tetrazolium hydroxide (XTT) reduction assay, crystal violet (CV) assay, and 
microscopic examination.
Results: A zone of C. albicans growth inhibition was observed at 10 and 20 g/mL of A. 
ascalonicum aqueous extract. The MIC of A. ascalonicum aqueous extract was found at 10 g/
mL. Significant differences were found between A. ascalonicum aqueous extract -treated and 
non-treated C. albicans in term of biofilm formation activity (XTT assay) and the quantity of 
biofilm formed (CV assay).
Conclusion: Using a simple and inexpensive extraction procedure, this study revealed the 
antifungal property of A. ascalonicum aqueous extract, which could be useful in exploring novel 
antifungal compound. 
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Introduction
There are about 1.5 million fungal species, where Candida 
is among the 300 pathogenic fungal species that causes 
~700 000 cases of infection, annually (1-3). Candida can 
be found as a commensal organism in healthy individuals 
(4). However, it may exploit the weakness of human 
defence mechanisms and develop candidiasis in the 
immunocompromised individual (5). Candidiasis may 
either be superficial, which involves the skin, hair, nails, 
oral and vaginal regions, or systemic, which affects the 
major body organs such as acute disseminated Candida 
septicemia infection (6-8). Among the pathogenic species 
of Candida, Candida albicans appears to be the leading 
causative agent of candidiasis (>50%) and possesses 
high mortality rate (9,10). This deadly systemic invasive 
candidiasis is suggested to be highly correlated with the 
wide-usage of the medical instruments such as catheter 
contaminated with Candida biofilm (11,12). Statistically, 
fungus (particularly C. albicans) is the third leading cause 
of catheter-related infections as well as second highest 
colonization-to-infection with the highest crude mortality 
(13,14). 
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Biofilm is defined as the structural microbial communities 
that are attached to a surface and encased in a matrix of 
exopolymeric material (13) and often associated with the 
pathogenicity of Candida (12,15). Known to be the virulent 
factor of Candida species, biofilm serves as the protective 
barrier for Candida species and contributes to boost the 
antifungal drug resistance. Additionally, biofilm also 
grants Candida species the ability to withstand the attack 
from host immune system and serves as reservoir site for 
re-infection (5,13,16). Interestingly, the greater ability of 
C. albicans to form biofilm is linked with its dominance 
as the leading cause of candidiasis, in comparison to C. 
glabrata and C. tropicalis (17). 
Despite the severity of candidiasis and fungal infections, 
fungi are often neglected by the public and funding bodies. 
In comparison to antibacterial remedies, there are only 
limited classes of antifungal agents available for physicians 
to combat Candida infections, namely polyenes, azoles, 
and echinocandins (18) which in turn may complicate the 
management of patients. In addition, the raising antifungal 
resistance reported worldwide has worsened the treatment 
outcomes (10). Therefore, several efforts, such as therapy 
through research and development of natural products, 
have been initiated to combat the threat posed by Candida 
species. The use of Allium ascalonicum (shallot) in food 
flavoring is known worldwide. Besides, shallot is also 
being employed in folk medicine since ancient time where 
shallot is described as “delicious food that stimulates the 
appetite during hot weather” (19). Shallot also possesses 
important medicinal value such as anti-oxidant (19) 
and anti-microbial property against Mycobacterium 
tuberculosis (21). Extensive efforts such as complex 
phytochemical analysis have been carried out to identify 
the potential active compounds, for example ascalin, and 
ascalonicoside A1/A2/B which may serve as the active 
antifungal compounds in A. ascalonicum (19,22). These 
studies have highlighted the potential active antifungal 
compounds found in shallot bulb, however tedious 
efforts and resources are required for the purification and 
retrieval of these compounds. Thus, this study aims to use 
a direct and cost-effective aqueous extraction method to 
retrieve crude A. ascalonicum aqueous extracts and test 
the antifungal and anti-biofilm properties of the retrieved 
compounds. The results from this study would be useful 
for the development of inexpensive and economically 
sound surface disinfectant, particularly in tackling and 
managing the biofilms of C. albicans, which persists in the 
clinical settings (13).
Materials and Methods
Preparations of Allium ascalonicum aqueous extract 
Allium ascalonicum aqueous extract was prepared freshly 
each time before use. A stock solution of 20 g/mL [weight/
volume (w/v)] of A. ascalonicum was prepared by grinding 
20 g fresh clean shallot and ground in 1 mL of Phosphate 
Buffer Saline (PBS). The extract was allowed to stand for 
30 minutes at room temperature and centrifuged at 5000 
rpm for 10 minutes. Then, the supernatant fluid was 
filtered through a sterile 0.22 µm membrane filter (Merck 
Milipore, US). The required concentrations (w/v) were 
prepared by serial dilution from the stock solutions.
Disc diffusion assay
Preparations of paper disc impregnated with Allium 
ascalonicum extract
The fresh stock solution of 20 g/mL (w/v) of A. 
ascalonicum extract was serial diluted to prepare the serial 
concentrations of the extract (2.5 g/mL, 5.0 g/mL, 10.0 
g/mL and 20.0 g/mL) by using two-fold serial dilution 
with PBS which served as diluent. Paper discs with 6 
mm diameter in size were prepared from ALBET® filter 
paper (Hahnemühle, Germany) by using the sterile hole 
puncher. The paper discs were autoclaved at 121°C for 
20 minutes for sterilization purpose before used. Then, 
the prepared paper discs were immersed in respective 
concentration solution for 10 minutes. Negative control 
disc was prepared by impregnating the paper disc with 20 
µL PBS solution while Clotrimazole (1.6 mg/mL) (Sigma 
Aldrich) served as positive control. The discs were lifted 
and left covered at room temperature for 20 minutes 
before used.
 
Preparation of Candida albicans strains
Candida albicans ATCC 14053 was cultured on Sabouraud 
Dextrose Agar (SDA) (Becton & Dickinson, USA) and 
was passaged twice from a single colony to ensure the 
purity. The identity of C. albicans was screened through 
CHROMagar™ Candida (CHROMagar, French), which 
appeared as green colony. Further test on C. albicans 
colony was performed by amplifying its ITS 1-4 (Internal 
Transcribed Spacer Regions) through polymerase chain 
reaction (PCR), which yielded a 530 bp amplicon (23). 
The C. albicans culture with correct identity was then 
incubated overnight on SDA at 37°C. Five colonies 
with the diameter larger than 1 mm were picked and 
suspended in 5 mL of PBS buffer. The yielded suspension 
was vortexed and cell density was adjusted by adding 
sufficient PBS buffer to achieve 0.5 McFarland Unit at 600 
nm wavelength through microplate reader (BioTek, USA) 
in order to standardize the cell suspension with 1x 106 to 
5 x 106 cells per mL. The inoculums were spread carefully 
onto SDA by using sterile glass hockey stick. 
Disc diffusion assay
The plant extract disc was applied on the agar and allowed 
to stand at room temperature for 15 minutes to allow 
diffusion. Then, the agar plate was incubated at 37°C 
for 24 hours and the diameter of zone of inhibition was 
measured.
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Broth macrodilution
The broth microdilution method was performed as 
described previously with minor modification (24). A 0.5 
McFarland Unit C. albicans cell suspension (1x 106 to 5 x 
106 cells per mL) was prepared as described above. Then, 
0.1 mL of the prepared cell suspension was mixed with 
0.9 ml of Sabouraud Dextrose Broth (SDB) (Becton & 
Dickinson, USA) for further dilution of cells to 1x 105 to 5 
x 105 cells per mL.
Preparation of diluted Allium ascalonicum aqueous extract
A total weight of 40 g fresh A. ascalonicum was ground in 
1 mL of PBS to prepare a stock solution of 40 g/ml (w/v). 
The extract was allowed to stand for 30 minutes at room 
temperature then followed by centrifugation at 5000 rpm 
for 10 minutes. The supernatant fluid was filtered through 
a sterile 0.22 µm membrane filter (Merck Milipore, US). 
The required concentration, weight/volume (w/v) was 
prepared by serial dilution from the stock solutions as 
shown in Table 1.
Broth inoculating
A volume of 1 mL of each extract was pipetted into a 
15 mL centrifuge tube, followed by 1 mL of C. albicans 
cell suspension and mixed well. The mixture tube was 
capped and left at room temperature for 15 minutes, then 
incubated at 37°C/180 rpm in a shaker incubator (Labnet, 
USA) for 24 hours. The cell growth activity was observed.
Biofilm formation in 96-well microtitre plate
The biofilm formation of C. albicans was performed as 
described by Pierce et al (25). A loopful of C. albicans 
cells was taken from culture stock of C. albicans in SDA 
and inoculated into 20 mL of SDB media. The culture was 
then incubated at 37°C/180 rpm for 16 hours in shaking 
incubator. After that, the cells were centrifuged at 3000 
rpm for 5 minutes and the supernatant was removed. The 
sediment cells were resuspended in 2 mL of PBS for the 
cell washing purpose. The cells were centrifuged at 3000 
rpm for 5 minutes again and the cell washing process 
was repeated twice. The cells were resuspended and 
adjusted to 0.5 McFarland unit with 37°C pre-warmed 
RPMI 1640 media. Then, 100 µL of cell suspension was 
loaded onto the 96-well microtitre plate. Next, 100 μL 
of final concentration of plant extract varies from 0 
MIC, 0.25 MIC, 0.5 MIC and 1 MIC were pipetted and 
mixed with cell suspension in respective wells. The 96-
well microtitre plate was covered with the lid and sealed 
with parafilm, followed by incubation for 24 hours at 
35°C. After incubation, the media from wells of 96-well 
microtitre plate was aspirated out carefully in order to 
prevent disruption of the biofilm formed at the bottom of 
well. The biofilm of each well was washed by adding 200 
µL of PBS and the washing process was repeated for three 
times. Then, the plate was placed in invert position with a 
blotting paper to remove the residual of PBS.
Measurement of Biofilm Activity by using XTT {2,3-bis 
(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino) 
carbonyl]-2H-tetrazolium hydroxide} reduction assay
The measurement of biofilm activity through XTT assay 
was performed as described previously (25). Briefly, 4.95 
mL of pre-made XTT (0.5 g/L) was thawed and 50 µl of 
menadione was added to thawed XTT. 100 µL of XTT/
menadione was added to washed-biofilm in the wells of 
96-well microtitre plate. Then, the plate was wrapped with 
aluminium foil and incubated in dark at 37°C for 3 hours. 
After that, 80 µL of supernatant was transferred to a new 
96-well microtitre plate and the plate was read by using 
microtitre reader (BioTek, USA) at the wavelength of 490 
nm. 
Quantification of bioflim by using crystal violet assay
The biofilm formed was quantified as described previously 
(26). Generally, the washed-biofilm was fixed by adding 
100 µL of methanol to each well for 15 minutes. Then, 
the supernatant was removed and the plate was left for 
air-dried. Subsequently, crystal violet (CV) solution was 
prepared by adding 1 mL of 90% CV in 50 mL distilled 
water and 100 µL of it was added to each well and left 
for 20 minutes. The excess CV was washed away under 
running tap water. A total of 150 µL of 33% acetic acid was 
Table 1. Preparation of serial concentrations of Allium ascalonicum extract
Concentration (g/mL) Stock solution at 40 g/mL (mL) PBS (mL) Mixed with SDB Final concentration yielded (g/mL)
0 0 1
1 mL of extract + 1 mL of C. 
albicans suspension in SDB
0
4 0.1 0.9 2
8 0.2 0.8 4
12 0.3 0.7 6
16 0.4 0.6 8
20 0.5 0.5 10
24 0.6 0.4 12
28 0.7 0.3 14
32 0.8 0.2 16
36 0.9 0.1 18
40 1 0 20
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added to each well to release the bounded CV. Then, the 
plate was read by using microtitre reader (BioTek, USA) at 
the wavelength of 590 nm.
Biofilm formation in 6-well microtitre plates
The suspension of C. albicans cell in RPMI1640 medium 
was prepared as described above. A volume of 2.5 mL of 
cell suspension was pipetted onto 6-well microtitre plates. 
Next, 2.5 mL of A. ascalonicum extract with 4 different 
final concentrations (0 MIC, 0.25 MIC, 0.5 MIC and 1 
MIC) were added into the cell suspension. The 6-well 
microtitre plate was covered with lid and incubated for 24 
hours at 35°C.
Microscopic observation of biofilm formation 
After 24 hours, 6-well microtitre plate was viewed and 
examined under inverted light microscope. Photographs 
were taken for each concentration of A. ascalonicum 
extract. 
Statistical analysis
Data analyses were performed using IBM SPSS Statistics 
(Version 23.0). The normality of the data was accessed 
using Shapiro-Wilk normality test. Results were analyzed 
using Kruskal-Wallis and Bonferroni correction test to 
determine the differences between treated and untreated 
groups and P values < 0.05 were considered as statistically 
significant. 
Results
Disc diffusion assay and broth macrodilution assay
In this study, the anti-C. albicans effect of A. ascalonicum 
aqueous extract was screened by using disc diffusion 
assay. A clear zones of inhibition, 1.2 cm and 1.5 
cm were observed at the 10 g/mL and 20 g/mL of A. 
ascalonicum aqueous extract, respectively (Figure 1). 
Broth macrodilution found that the minimum inhibitory 
concentration (MIC), the lowest concentration of A. 
ascalonicum aqueous extract that inhibited the growth of 
Figure 1. The disc diffusion assay showed 10 g/mL and 20 g/mL of 
Allium ascalonicum aqueous extracts inhibited the growth of Candida 
albicans.
C. albicans was 10 g/mL (Table 2).
Biofilm formation assay
The Shapiro-Wilk test has indicated that the data generated 
for both XTT and CV assays were not normally distributed 
(P < 0.05). Therefore, the non-parametric statistical 
tests, Kruskal-Wallis and Bonferroni correction tests 
were applied in this study. Through the XTT reduction 
assay, significant reduction in biofilm forming activity 
was observed when biofilm formation of C. albicans was 
challenged with A. ascalonicum extract at 1 MIC and 
2 MIC, in comparison to untreated biofilm (Figure 2). 
Besides, CV assay found that the amount of biofilm formed 
by C. albicans was observed to be reduced significantly 
with the treatment of A. ascalonicum extract at 1 MIC 
and 2 MIC (Figure 3). The microscopic examination of 
C. albicans biofilm treated with A. ascalonicum extract 
was carried out by using inverted light microscope at 
40X magnification to examine the anti-biofilm effect of 
A. ascalonicum extract, qualitatively. The results showed 
Table 2. Summary of the Minimum Inhibitory Concentration (MIC) of 
Allium ascalonicum aqueous extracts against Candida albicans 
Plant Extracts Concentration, g/mL Candida albicans growth
Negative Control Resistant
2 Resistant
4 Resistant
6 Resistant
8 Resistant
10 Susceptible
12 Susceptible
14 Susceptible
16 Susceptible
18 Susceptible
20 Susceptible
Positive Control (Clotrimazole) Susceptible
The growth of C. albicans was inhibited by 10 g/mL of A. ascalonicum.
Figure 2. Determination of the effect of Allium ascalonicum aqueous 
extract on Candida albicans biofilm formation activity using XTT 
Assay. Box-plot shows the biofilm formation activity under different 
concentration of treatment after incubation for 24 hours, at 490 nm 
by using XTT reduction assay.  A significant reduction (*) of biofilm 
formation activity was observed at 1 MIC and 2 MIC (P value< 0.05).
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that the biofilm density of C. albicans was reduced with 
the increasing concentration of A. ascalonicum extract, 
compared to biofilm formation without any treatment 
(Figure 4).
Discussion
Candidiasis is a type of opportunistic infection in human 
caused by Candida species. C. albicans is the major 
etiological agent which constitutes 44.2%, among 1114 
clinical isolations in Malaysia (27). In past 2 decades, 
the prevalence of candidiasis has risen and this led to 
the increase in the usage of antifungal therapies such as 
azole drug. With the extensive usage of azole drug, the 
problem with the development of resistance toward azoles 
by Candida species has also risen with both primary and 
secondary resistance (28). Furthermore, the persistence of 
Candida species biofilm on medical devices surfaces such 
as indwelling catheter has also contributed to the rising 
number of invasive candidiasis cases (12). The formation of 
biofilm is also linked to the enhanced capability of Candida 
to resist antifungal (29), which leads to the challenge in the 
treatment of candidiasis. Thus, the purpose of this study 
was to evaluate antifungal and anti-biofilm properties 
of the aqueous extract from A. ascalonicum against the 
predominance Candida species, Candida albicans which 
can be applied as an economic surface disinfectant or novel 
antifungal compound. The disc diffusion assay suggested 
that the effective concentration of A. ascolonicum aqueous 
extract to inhibit the growth of C. albicans was at 10 g/mL 
(Figure 1) and broth microdilution assay was determined 
the MIC of A. ascalonicum aqueous extract to be 10 g/mL 
(Table 2), where the growth of C. albicans was completely 
stunted. This is in line with the previous study conducted 
by Mahmoudabadi and Nasery (30) where fresh crude 
shallot juice (A. ascalonicum Linn. (Liliaceae)) presented 
with antifungal activity against C. albicans, as well as 
saprophytic fungi and dermatophytes. However, the 
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Figure 3. Determination of the effect of Allium ascalonicum aqueous 
extract on Candida albicans biofilm formation using CV assay. Box-
plot shows the amount of biofilm formed under different concentration 
of treatment after incubation for 24 hours, at 590 nm by using CV 
assay. A significant reduction (*) of biofilm formed was observed at 1 
MIC and 2 MIC (P value < 0.05).
Figure 4. Biofilm formation observed after 24 hours with respective 
treatment applied. A.) without treatment B.) 0.25 MIC, C.) 0.5 MIC, D.) 
1 MIC and E.) 2 MIC at 40X magnification. A reduction of activity was 
observed with increasing concentration of treatment.
MIC was not comparable as the authors designated the 
concentration of A. ascalonicum aqueous extract in the 
form of percentage, rather than in weight per volume. 
Besides, several studies have also highlighted the potential 
antifungal effect of A. ascalonicum in combating C. albicans 
(31,32), at mg/mL level. Notably, the extraction methods 
in both studies were different from this study, where A. 
ascalonicum has undergone complex and time-consuming 
extraction procedure while current study applied the 
direct yet simple (<1-hour procedure) aqueous method 
to extract the antifungal compound from A. ascalonicum. 
Followed by the susceptibility test, the potential of A. 
ascalonicum extract to combat the biofilm of C. albicans 
was evaluated through both XTT assay and CV assay. 
XTT is a yellow salt that is reduced by mitochondrial 
dehydrogenase of metabolically active yeast cell (33) 
and is employed in quantitating the biofilm formation 
activity (34) while CV assay is a basic dye which binds 
to negatively charged extracellular molecule in mature 
biofilm (35) and CV assay can be applied in measuring the 
amount of biofilm formed (25,26). In this study, both XTT 
assay and CV assay showed that A. ascalonicum aqueous 
extract exhibited an inhibitory effect on biofilm formation 
of C. albicans (Figures 3 and 4). Moreover, the increased 
in the concentration of A. ascalonicum extract has resulted 
in a greater reduction of biofilm formation activity and 
biofilm density (Figures 2 and 3). These observations 
were further verified with the microscopic examination 
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as biofilm density decreased with the treatment of A. 
ascalonicum extract (Figure 4). 
Conclusion
In short, through a simple and cost-effective aqueous 
extraction method, this study revealed the potential of 
A. ascalonicum to inhibit the growth of C. albicans at the 
concentration of 10 g/mL as well as to inhibit the biofilm 
formation activity of C. albicans. The results from this 
study are beneficial for the development of economically-
sound surface disinfectant which could be useful in 
managing the Candida biofilm contamination.
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